Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP_gen or combined TdaP_gen vaccines.

ABSTRACT:

Background

Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine.

Methods

Participants of a phase 2/3 randomised-controlled clinical trial with a monovalent pertussis vaccine containing genetically inactivated pertussis toxin (aP_gen) or its tetanus and diphtheria toxoids combination (TdaP_gen), or a chemically detoxified comparator vaccine (Tdap_chem), (originally conducted between July and August 2015) were invited to participate in observational studies of persisting antibody responses 2 and 3 years after vaccination. Serum IgG against

SUBMITTER: Pitisuttithum P 

PROVIDER: S-EPMC8343263 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature